Leo Brokerage LLC Invests $212,000 in GSK plc (NYSE:GSK)

Leo Brokerage LLC bought a new position in GSK plc (NYSE:GSKGet Rating) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,873 shares of the pharmaceutical company’s stock, valued at approximately $212,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Harrison & Co Wealth Management LLC grew its position in GSK by 1.7% in the second quarter. Harrison & Co Wealth Management LLC now owns 22,584 shares of the pharmaceutical company’s stock worth $983,000 after acquiring an additional 388 shares in the last quarter. Brookstone Capital Management boosted its position in shares of GSK by 147.5% during the second quarter. Brookstone Capital Management now owns 49,703 shares of the pharmaceutical company’s stock valued at $2,104,000 after buying an additional 29,622 shares during the period. Thrive Wealth Management LLC grew its stake in shares of GSK by 152.2% during the second quarter. Thrive Wealth Management LLC now owns 13,370 shares of the pharmaceutical company’s stock valued at $582,000 after buying an additional 8,069 shares during the last quarter. Greylin Investment Mangement Inc. grew its stake in shares of GSK by 86.2% during the second quarter. Greylin Investment Mangement Inc. now owns 38,155 shares of the pharmaceutical company’s stock valued at $1,661,000 after buying an additional 17,665 shares during the last quarter. Finally, Stonnington Group LLC grew its stake in shares of GSK by 187.9% during the second quarter. Stonnington Group LLC now owns 20,150 shares of the pharmaceutical company’s stock valued at $873,000 after buying an additional 13,150 shares during the last quarter. Hedge funds and other institutional investors own 16.86% of the company’s stock.

GSK Stock Down 0.6 %

GSK stock opened at $30.83 on Monday. The business has a fifty day moving average of $36.90 and a two-hundred day moving average of $41.24. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 0.83. The firm has a market cap of $62.70 billion, a P/E ratio of 10.21, a P/E/G ratio of 1.17 and a beta of 0.61. GSK plc has a twelve month low of $30.49 and a twelve month high of $46.97.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 6th. Shareholders of record on Friday, August 19th will be issued a dividend of $0.383 per share. The ex-dividend date of this dividend is Thursday, August 18th. This represents a $1.53 dividend on an annualized basis and a yield of 4.97%. This is a positive change from GSK’s previous quarterly dividend of $0.35. GSK’s dividend payout ratio is currently 50.66%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GSK. AlphaValue cut GSK to a “reduce” rating in a research note on Tuesday, July 19th. TheStreet cut GSK from a “b” rating to a “c+” rating in a research note on Monday, August 29th. Deutsche Bank Aktiengesellschaft cut their target price on GSK from GBX 1,750 ($21.15) to GBX 1,500 ($18.12) in a research note on Wednesday, September 7th. UBS Group cut their target price on GSK from GBX 1,876 ($22.67) to GBX 1,850 ($22.35) in a research note on Wednesday, July 20th. Finally, StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $1,700.00.

GSK Company Profile

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKGet Rating).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.